Clinical Trials

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT04765059 2026-04-21

COMPEL

98 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT06838273 2026-04-20

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

720 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05261399 2026-04-06

SAFFRON

345 enrolled

Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

NCT05629234 2026-04-06

ROSY-T

37 enrolled

Tumor-Agnostic

Neoplasms

NCT02511106 2026-03-30

ADAURA

682 enrolled 20 charts 2 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT06417814 2026-03-02

TROPION-Lung15

744 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-02-27

LAURA

216 enrolled 25 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT06970639 2026-02-12

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

380 enrolled

Phase 3 Not yet recruiting

NSCLC Patients With Brain Metastasis

NCT07376382 2026-02-02

SYNSTAR-02

450 enrolled

NSCLC

NCT02411448 2026-01-16

RELAY

545 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05120349 2026-01-12

ADAURA2

390 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06670196 2025-12-05

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

420 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06350097 2025-11-17

TROPION-Lung14

582 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04035486 2025-10-10

FLAURA2

587 enrolled 44 charts 2 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04351555 2025-05-23

NeoADAURA

358 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05015608 2025-05-23

SACHI

250 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06829459 2025-04-08

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02151981 2025-01-07

AURA3

Phase 3 Completed

421 enrolled 18 charts

Anticancer Treatment

NCT06735391 2024-12-16

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

516 enrolled

Locally Advanced or Metastatic Non-squamous NSCLC

NCT02454933 2024-09-19

CAURAL

Phase 3 Completed

29 enrolled 10 charts

Locally Advanced or Metastatic EGFR T790M+ NSCLC

NCT06093503 2024-06-26

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Phase 3 Terminated

8 enrolled 7 charts

Phase 3 Not yet recruiting

NSCLC

NCT06380348 2024-04-23

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

398 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04816214 2024-03-05

GEOMETRY-E

Phase 3 Terminated

6 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05382728 2024-01-30

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

680 enrolled